Stopping antiviral treatment in chronic hepatitis B
Part of Digestive system, Infections clinical trials.
This trial studies what happens after stopping long-term hepatitis B antiviral medicine in people whose virus has stayed controlled. It also follows patients over time to see how well they remain stable and safe after stopping.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic hepatitis B and previously took antiviral tablets called nucleos(t)ide analogs
- You stayed on the antiviral medication for at least 2 years
- Your hepatitis B blood tests stayed suppressed for a required amount of time after key markers changed or stayed negative
- You do not have liver scarring (cirrhosis) or liver cancer (HCC)
- You do not have other illnesses that are actively affecting your liver right now
- You are not pregnant or breastfeeding, and you do not have HIV or immune system problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares outcomes for people with chronic hepatitis B who have long-term, stable viral suppression: stopping their antiviral medicine versus continuing it. It may help answer whether it’s safe to stop treatment in the right patients.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This trial is for people with chronic hepatitis B who have already cleared the virus with interferon treatment. It tests ongoing strategies to help maintain their health and prevent the virus from coming back.
This study follows patients who completed a previous trial of peginterferon alfa-2b and tenofovir for chronic hepatitis B. It checks long-term health and offers further treatment options based on your response to the earlier therapy.
This study tests a new medicine called ZM-H1505R for people with chronic hepatitis B who are already taking standard antiviral therapy. It aims to see if the new drug can help control the infection better.
This study tests whether a medicine called peginterferon can help lower the chance of hepatitis B coming back after you stop your current antiviral treatment. It may be an option for people with well-controlled hepatitis B and low levels of surface antigen.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.